Q2 Earnings Estimate for Zoetis Issued By Leerink Partnrs

Zoetis Inc. (NYSE:ZTS - Free Report) - Equities researchers at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Zoetis in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings of $1.60 per share for the quarter, down from their previous forecast of $1.61. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.38 EPS.

ZTS has been the topic of several other research reports. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday. Stifel Nicolaus lowered their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $212.13.

Zoetis Price Performance

Shares of NYSE ZTS traded down $1.73 during midday trading on Thursday, hitting $159.96. The company had a trading volume of 4,243,109 shares, compared to its average volume of 2,492,973. The firm has a market capitalization of $71.37 billion, a price-to-earnings ratio of 29.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis has a twelve month low of $139.70 and a twelve month high of $200.33. The business has a 50-day simple moving average of $157.27 and a two-hundred day simple moving average of $166.06. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,862 shares of company stock worth $312,254. 0.18% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ZTS. Mission Wealth Management LP raised its stake in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after acquiring an additional 59 shares during the last quarter. VeraBank N.A. grew its position in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after buying an additional 62 shares during the period. HUB Investment Partners LLC increased its stake in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC raised its stake in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after buying an additional 63 shares during the period. Finally, Coppell Advisory Solutions LLC grew its stake in Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.